Creating a closed-process, semi-automated workflow for human MSC expansion, harvest, and final fill

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Costly all-in-one cell processing systems are commonly used in the development and production of cell and gene therapies. Large scale production of these therapies requires bioreactors to generate enough biological material, with reproducible and aseptic workflows, often warranting precious and costly clean-room space. While commercially available bioreactor platforms allow for large scale production of cell therapies, they are often limited in scaling processes, are inherently inefficient, require skilled personnel, and lack flexibility. By employing a decentralized manufacturing strategy, cost-effective production of advanced therapeutics using modular closed-system production workflows may be achieved at a fraction of the cost of all-in-one systems.

This webinar demonstrates the use of off-the-shelf consumables in a closed semi-automated modular workflow as an alternative, more cost-effective approach compared to "all-in-one" systems. Additionally, a case study describing the results of expanding bone-marrow derived mesenchymal stem cell (MSC) in a modular closed system will be presented demonstrating that the modular system is suitable for both suspension and adherent cell growth, and capable of scale up and scale out from lab to commercial levels.

• The creation and use of semi-automated modular workflows
• When to deploy off-the-shelf consumables
• How to perform a closed-system MSC expansion process in standard BSL-2 lab settings

Julien Muzard

Field Applications Technologist at Entegris

Julien is a French biotechnologist with a PhD from Paris-Diderot. After postdoctoral training in single-molecule nanobiophysics and computational biology, Julien continued his career at the Center of Molecular Innovation in Dublin and the Molecular Foundry in California. He returned to Europe in 2015 to further establish his career in bionanotechnology, helping to develop the FDA-approved drug Glenzocimab. He joined Entegris in 2021.

Donnie Beers

LS Applications Leader, Cell and Gene therapy at Entegris

Donnie has 15 years’ experience in single-use and automation technology. He joined Entegris in 2019 as senior product manager and has since taken the lead in facilitating cell and gene therapy applications. He has previously held roles in engineering management, project management, and manufacturing within a Current Good Manufacturing Practice environment. Donnie earned his Bachelor of Science in Biochemistry from University of Wisconsin–Madison.

in 10

Days

Register

SPEAKERS

Julien Muzard

Field Applications Technologist at Entegris

Donnie Beers

LS Applications Leader, Cell and Gene therapy at Entegris

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 38

Days

Register

End-to-end automated manufacturing of low-seed CAR-T cells

David Smith

27 June

in 38

Days

Register

Discover the road to success for viral vector production: strategies, insights, and regulatory considerations

S Shore, A Gilbert, J Bishop

20 June

in 31

Days

Register

Specifications don’t tell the whole story: how to choose GMP process and QC equipment

M Kay Bates, W Marin, K Whitlatch

18 June

in 29

Days

Register

Revolutionary innovations are underway to industrialize cell and gene therapies

Mark Santos

13 June

in 24

Days

Register